[
  {
    "drug_name": "Darolutamide",
    "application_number": "213072",
    "application_type": "NDA",
    "approval_status": "approved",
    "deficiency_categories": [
      "oncology_specific"
    ],
    "openfda_generic_name": "Darolutamide",
    "enriched": {
      "smiles": null,
      "open_targets_id": "CHEMBL4297185",
      "targets": [
        {
          "symbol": "AR",
          "id": "ENSG00000169083",
          "biotype": "protein_coding",
          "genetic_constraint": [],
          "cancer_hallmarks": [
            {
              "label": "escaping programmed cell death",
              "description": "inhibits apoptosis"
            },
            {
              "label": "proliferative signalling",
              "description": "stimulates proliferation of prostatic epithelial cells"
            }
          ],
          "top_pathways": [
            "Metabolism of proteins: Ub-specific processing proteases",
            "Cellular responses to stimuli: HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand",
            "Metabolism of proteins: SUMOylation of intracellular receptors",
            "Gene expression (Transcription): Nuclear Receptor transcription pathway",
            "Gene expression (Transcription): RUNX2 regulates osteoblast differentiation"
          ],
          "oncology_evidence": {
            "disease_name": "prostate cancer",
            "overall_association_score": 0.7995487838083033,
            "genetic_association_score": 0.8390577531745912,
            "somatic_mutation_score": 0.42555155832813474
          }
        }
      ]
    }
  },
  {
    "drug_name": "Sintilimab",
    "application_number": "761222",
    "application_type": "BLA",
    "approval_status": "unapproved",
    "deficiency_categories": [
      "oncology_specific",
      "clinical_trial_design"
    ],
    "openfda_generic_name": "Sintilimab",
    "enriched": {
      "smiles": null,
      "open_targets_id": "CHEMBL4297829",
      "targets": [
        {
          "symbol": "PDCD1",
          "id": "ENSG00000188389",
          "biotype": "protein_coding",
          "genetic_constraint": [
            {
              "constraintType": "syn",
              "score": -0.021219000220298767,
              "oe": 1.003000020980835,
              "oeLower": 0.8830000162124634,
              "oeUpper": 1.1399999856948853
            },
            {
              "constraintType": "mis",
              "score": 1.4210000038146973,
              "oe": 0.8026400208473206,
              "oeLower": 0.7310000061988831,
              "oeUpper": 0.8820000290870667
            },
            {
              "constraintType": "lof",
              "score": 0.029637999832630157,
              "oe": 0.5252100229263306,
              "oeLower": 0.3230000138282776,
              "oeUpper": 0.890999972820282
            }
          ],
          "cancer_hallmarks": [],
          "top_pathways": [
            "Disease: Potential therapeutics for SARS",
            "Immune System: Co-inhibition by PD-1",
            "Immune System: PD-L1(CD274) glycosylation and translocation to plasma membrane"
          ],
          "oncology_evidence": {
            "disease_name": "non-small cell lung carcinoma",
            "overall_association_score": 0.6233407724178877,
            "genetic_association_score": 0.0,
            "somatic_mutation_score": 0.0
          }
        }
      ]
    }
  },
  {
    "drug_name": "Retifanlimab",
    "application_number": "761155",
    "application_type": "BLA",
    "approval_status": "unapproved",
    "deficiency_categories": [
      "oncology_specific",
      "efficacy"
    ],
    "openfda_generic_name": "Retifanlimab",
    "enriched": {
      "smiles": null,
      "open_targets_id": "CHEMBL4298037",
      "targets": [
        {
          "symbol": "PDCD1",
          "id": "ENSG00000188389",
          "biotype": "protein_coding",
          "genetic_constraint": [
            {
              "constraintType": "syn",
              "score": -0.021219000220298767,
              "oe": 1.003000020980835,
              "oeLower": 0.8830000162124634,
              "oeUpper": 1.1399999856948853
            },
            {
              "constraintType": "mis",
              "score": 1.4210000038146973,
              "oe": 0.8026400208473206,
              "oeLower": 0.7310000061988831,
              "oeUpper": 0.8820000290870667
            },
            {
              "constraintType": "lof",
              "score": 0.029637999832630157,
              "oe": 0.5252100229263306,
              "oeLower": 0.3230000138282776,
              "oeUpper": 0.890999972820282
            }
          ],
          "cancer_hallmarks": [],
          "top_pathways": [
            "Disease: Potential therapeutics for SARS",
            "Immune System: Co-inhibition by PD-1",
            "Immune System: PD-L1(CD274) glycosylation and translocation to plasma membrane"
          ],
          "oncology_evidence": {
            "disease_name": "non-small cell lung carcinoma",
            "overall_association_score": 0.6233407724178877,
            "genetic_association_score": 0.0,
            "somatic_mutation_score": 0.0
          }
        }
      ]
    }
  },
  {
    "drug_name": "Granisetron",
    "application_number": "207987",
    "application_type": "NDA",
    "approval_status": "approved",
    "deficiency_categories": [
      "oncology_specific",
      "cmc_manufacturing"
    ],
    "openfda_generic_name": "Granisetron",
    "enriched": {
      "smiles": null,
      "open_targets_id": "CHEMBL289469",
      "targets": [
        {
          "symbol": "HTR3A",
          "id": "ENSG00000166736",
          "biotype": "protein_coding",
          "genetic_constraint": [
            {
              "constraintType": "syn",
              "score": -1.0130000114440918,
              "oe": 1.1162999868392944,
              "oeLower": 1.0130000114440918,
              "oeUpper": 1.2309999465942383
            },
            {
              "constraintType": "mis",
              "score": -0.21502000093460083,
              "oe": 1.023800015449524,
              "oeLower": 0.9580000042915344,
              "oeUpper": 1.093999981880188
            },
            {
              "constraintType": "lof",
              "score": 8.982799747092596e-12,
              "oe": 0.7971900105476379,
              "oeLower": 0.6200000047683716,
              "oeUpper": 1.034000039100647
            }
          ],
          "cancer_hallmarks": [],
          "top_pathways": [
            "Neuronal System: Neurotransmitter receptors and postsynaptic signal transmission"
          ],
          "oncology_evidence": {
            "disease_name": "cancer",
            "overall_association_score": 0.5948915719593042,
            "genetic_association_score": 0.0,
            "somatic_mutation_score": 0.0
          }
        }
      ]
    }
  }
]